2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Metabolism, Microbiome, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Health Outcomes Research, Study Population, Human, Adult, Animal Model
PAPER

4946 High response rate but high relapse risk: The role of allogeneic transplant in DDX41-mutant myeloid neoplasms

Alex Bataller, MD, PhD, Akihiro Miyashita2, Emily S Ortiz3, Hiam Abdel-Salam, M.S4, Ian Bouligny, M.D.5, Alexandre Bazinet, MD, MSc6, Kelly Sharon Chien, MD7, Guillermo Montalban-Bravo, MD8, Nicholas Short, MD9, Hannah Goulart, MD10, Jennifer Marvin-Peek, MD11, Wei Ying Jen, BM BCh, FRCPath12, Ghayas C. Issa, MD13, Tapan Kadia I, MD14, Farhad Ravandi, MD15, Naval Daver, MD16, Warren Fiskus, PhD17, Christopher P Mill, PhD18, Koichi Takahashi, MD,PhD19, Sanam Loghavi, MD20, Uday Popat, MD, MBA21, Guillermo Garcia-Manero, MD22, Courtney DiNardo, MD, MSCE23
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Myeloid neoplasms with germline (GL) DDX41 mutations (DDX41mut) are a WHO-recognized entity with distinct clinical and biological features. The prognosis is controversial, though we and others have shown venetoclax (Ven) added to low-intensity therapy yields favorable outcomes. The role of allogeneic HSCT in this population remains debated. We analyzed outcomes in DDX41mut patients across different types of therapy, focusing on the impact of HSCT.

Methods: This single-center retrospective study included patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between 1998-2026 who underwent NGS testing at any timepoint and had a detectable DDX41 variant. GL status was confirmed by skin fibroblast testing or persistent heterozygous mutation in remission. GL variants were classified as pathogenic (consisting of pathogenic and likely pathogenic per ACMG criteria), of unknown significance (VUS), or benign per genomic database annotations.

Results: We identified 336 patients with DDX41 variants: GL pathogenic (n=194 58%), GL VUS (n=61, 18%), GL benign (n=28, 8%), and somatic (n=53, 16%). Analyses were restricted to patients with GL pathogenic DDX41 variants, including patients diagnosed with AML (n=100) and MDS (n=94). Among patients with available characteristics at diagnosis, median age was 69 years (range, 39-88), with a male predominance (69%). Karyotype was normal in 77% and complex in 2%. The most frequent GL DDX41 variants were p.D140fs (20%), p.M1I (20%), p.M316fs (5%), and p.Q41* (5%). A second somatic DDX41 variant was present in 69% of patients, most commonly p.R525H (56%). Frequent co-mutations included ASXL1 (16%), SRSF2 (14%), and TP53 (13%; 4% multi-hit). Notably, 36% of patients had no co-mutation besides DDX41.

The overall response rate (ORR) in frontline DDX41mut AML was 90% and 100% for patients treated with intensive therapy (IT, n=20) and IT + Ven (n=8), respectively. Among frontline DDX41mut AML patients treated with low-intensity therapy (LIT, n=15) or LIT + Ven (n=57), ORR was 67% and 89%, respectively. In DDX41mut MDS, ORR was 69% and 95% for patients treated with LIT (n=43) and LIT + Ven (n=21), respectively. DDX41mut patients also demonstrated sustained treatment sensitivity, with an ORR of 52% and 33% to AML salvage 1 and 2 therapy, respectively, and 50% and 17% to MDS salvage 1 and 2, respectively.

Median follow-up was 53 months. Median overall survival (OS) and 2-year OS were 44 months and 79% for frontline DDX41mut AML, and 54 months and 86% for frontline DDX41mut MDS. In frontline DDX41mut AML, OS did not differ significantly between patients treated with IT ± Ven and LIT ± Ven (median OS 45 vs 39 months; 2-year OS 81% vs 78%; P = ns).

Overall, 52 patients proceeded to HSCT after frontline therapy: 11/28 (39%) of DDX41mut AML patients treated with IT ± Ven, 24/72 (34%) treated with LIT ± Ven, and 17/86 (20%) of DDX41mut MDS patients. In a landmark analysis restricted to patients aged ≤75 who responded to frontline therapy, HSCT was associated with improved OS in DDX41mut AML (median OS not reached vs 39 months; 5-year OS 80% vs 32%; P < 0.001), and a trend toward better OS in DDX41mut MDS (median OS 71 vs 57 months; 5-year OS 92% vs 51%; P = 0.21).

Using landmark-restricted cumulative incidence of relapse and death as competing events, with Fine-Gray regression to assess the impact of HSCT, relapse risk in DDX41mut AML was significantly lower among patients who underwent HSCT (2-year cumulative incidence 4% vs 48%; P < 0.001; HR 0.1, 95% CI 0.03-0.3; P < 0.001), with no difference in death without relapse (2-year cumulative incidence 10% vs 6%; P = ns). This effect was maintained when IT and LIT patients were analyzed separately. In DDX41mut MDS, 2-year cumulative incidence of relapse was likewise lower among patients who underwent HSCT (7% vs 40%; P = 0.001; HR 0.19, 95% CI 0.06-0.62; P = 0.006).

Conclusion: Patients with GL DDX41mut AML and MDS show high response rates to frontline IT and LIT and demonstrate relative sensitivity to salvage therapies. In GL DDX41mut myeloid neoplasms, HSCT is associated with improved survival, driven by significantly reduced relapse risk, leading to more durable long-term remissions.
Alex Bataller, MD, PhD: No relevant conflicts of interest to declare.